10 Best High-Growth Stocks to Diversify Away From Big Tech

Page 3 of 3

4. Interactive Brokers Group, Inc. (NASDAQ:IBKR)

Revenue Growth Over the Past 3 Years: 35.57%

Number of Hedge Fund Holders: 75

Interactive Brokers keeps adding clients faster than markets increase volatility. Customer accounts climbed 35% to 5.58 million, customer equity by 27% to $964.7 billion, and customer margin loans by 36% to $105.2 billion. The pretax margin came in at 78%, marking the eighth straight quarter above 70%.

That said, Q3 results were mixed, with revenue higher than expected and earnings falling short. Net revenue increased to $1.91 billion, with net interest income growing 19% to $1.15 billion and commission revenue up 12% to $602 million. Adjusted earnings per share of $0.67 missed expectations, capping a run of five consecutive beats. DARTs came in at 11% below the second quarter, indicating a slower trading volume. Meanwhile, the company boosted its quarterly dividend by 71%, to $0.15 from $0.0875.

October showed the same split. DARTs were 4% lower than a year before, client equity fell 4% to $928.6 billion in September, and accounts increased 34% to 5.678 million. Whether the share premium to five-year valuation is justified is the question in our analysis of Interactive Brokers. Read about it here.

3. Robinhood Markets, Inc. (NASDAQ:HOOD)

Revenue Growth Over the Past 3 Years: 48.27%

Number of Hedge Fund Holders: 90

Prediction markets are now a legitimate revenue stream for Robinhood. Event contracts generated $173 million in the third quarter, up from $156 million in the second, with a record 16.4 billion contracts traded. Robinhood now has 14 business lines with at least $100 million in annualized revenue, and Gold subscribers increased 34% to  a record 5.2 million.

While the quarter achieved a revenue record, it failed to meet earnings expectations. Revenue increased to $1.42 billion, with EPS of $0.51 versus $0.55 projected, while crypto revenue of $120 million fell 55% from a year ago. October net deposits surpassed $13 billion month to date, including $6 billion from the Dell family’s contribution to Trump Accounts.

The stock has not kept pace with the business. Prior to the announcement, shares closed near $94.61, down about 18% for the year and 37% below their 52-week high. Robinhood is leaning further into event contracts, and its expanded prediction markets collaboration with Crypto.com gives the product a broader distribution network.

2. Nu Holdings Ltd. (NYSE:NU)

Revenue Growth Over the Past 3 Years: 48.27%

Number of Hedge Fund Holders: 90

Nu is expanding on three fronts simultaneously. Nu Mexico began operations as a full bank on August 6, and customer deposit insurance coverage increased 16-fold. Overall, Mexico added 870 thousand consumers to reach 16.6 million, Colombia reached 6.1 million, and Nu US launched on September 10 and reached customers in all 50 states.

The results support the story. Net income reached a record $1.1 billion, up 31% on an FX-neutral basis, with a 32% return on equity, while gross revenue increased 37% to $6.3 billion. The efficiency ratio improved to 19.3%, and deposits grew by 19% to $47.5 billion.

Analysts also remained positive. Needham’s Kyle Peterson reiterated a Buy rating and a $19 price target, saying the results alleviated near-term concerns about Brazil’s macroeconomic outlook. The stock was still down more than 29% for the year before to the report, which helps explain the scale of the rebound, and our coverage of Nu’s double-digit rally digs into what drove it.

1.  Eli Lilly and Company (NYSE:LLY)

Revenue Growth Over the Past 3 Years: 31.69%

Number of Hedge Fund Holders: 137

Eli Lilly is the Indianapolis-based company behind the the GLP-1 drugs Mounjaro and Zepbound. Tirzepatide, the active component in both, is the engine. Mounjaro’s revenue increased by 65% to $10.7 billion, while Zepbound’s jumped by 49% to $5.35 billion. The new oral GLP-1 Foundayo raised $184 million, up from $98 million the previous quarter, while Kisunla for Alzheimer’s increased 175% to $193 million. A head-to-head Phase 3 trial of retatrutide against Ozempic in type 2 diabetes was likewise positive.

Eli Lilly raised its outlook sharply. Revenue rose 39% to $24.4 billion in the third quarter, while adjusted EPS of $7.48 exceeded expectations for the fifth time in a row. The company’s full-year revenue projection climbed to $91 billion to $92 billion from $85 billion to $87 billion, and the stock gained approximately 4% pre-market. Revenue included one-time Jardiance milestones, with no more remaining.

However, pricing is the offset. Realized prices in the US declined 7%, while prices outside the States fell by 29%. Whether the momentum can outlast the sector rotation is the question in our look at how the rotation weighed on Lilly in the third quarter.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Follow Insider Monkey on Google News.

Page 3 of 3